Phathom Pharmaceuticals, Inc.·4

May 21, 4:30 PM ET

KARBE FRANK 4

Research Summary

AI-generated summary

Updated

Phathom (PHAT) Director Karbe Frank Receives RSU Award

What Happened Director Karbe Frank received an award of 24,122 Restricted Stock Units (RSUs) on May 19, 2026, reported on a Form 4 filed May 21, 2026. The filing shows an acquisition-type transaction (code A) with $0 cash paid at grant — the RSUs are a compensation award, not an open-market purchase.

Key Details

  • Transaction date: May 19, 2026; Form 4 filed: May 21, 2026 (appears timely under the two-business-day Form 4 rule).
  • Transaction type/code: Grant/Award (A). Reported acquisition amount: 24,122 RSUs at $0.00.
  • Vesting: 100% of RSUs vest on the earlier of (A) the first anniversary of grant or (B) the next annual meeting of stockholders, subject to continued board service (footnote F1).
  • Each RSU represents a contingent right to receive one share of common stock upon vesting.
  • Shares owned after the transaction: not specified in the provided filing excerpt.
  • No indication of a 10b5-1 plan, tax-withholding sale, or late filing in the information provided.

Context RSU grants to directors are standard compensation and do not reflect an open-market buy or sale. Because these RSUs vest in the future and convert to shares only if the director remains in service, they are a retention/compensation tool rather than an immediate liquidity or market-timing signal.